Should We Add Fludrocortisone to Hydrocortisone for Treatment of Septic Shock?

Matthay, Michael A.; Dahabreh, Issa J; Thompson, B Taylor

doi:10.1001/jamainternmed.2023.0257

JAMA Intern Med

2023

DOI: 10.1001/jamainternmed.2023.0257

|View full text |Cite

Should We Add Fludrocortisone to Hydrocortisone for Treatment of Septic Shock?

Michael A. Matthay

Issa J Dahabreh

B Taylor Thompson

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with sepsis, mineralocorticoid steroidogenesis is more impaired than glucocorticoid synthesis, and this deficiency is associated with sepsis nonsurvival ( 10 ). Therefore, the potential benefits of fludrocortisone in treating septic shock are beginning to be highly valued and are believed to stem from the restoration of homeostasis and augmentation of innate immunity ( 11 ). Thus, rigorously assessing the combined use of fludrocortisone and hydrocortisone in treating septic shock in adults is imperative.…”

mentioning

confidence: 99%

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation*

Lai,

Lai

et al. 2023

Critical Care Medicine

View full text Add to dashboard Cite

Objectives: This systematic review and Bayesian network meta-analysis evaluated the efficacy and safety of hydrocortisone combined with fludrocortisone or hydrocortisone alone, compared with placebo in adult patients with septic shock. Data Sources: By extending a prior Cochrane review, databases, including PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov, along with other relevant websites, were searched until August 31, 2023. Study Selection: Randomized controlled trials (RCTs) and observational studies using target trial emulation were included. Data Extraction: The primary outcome was short-term mortality with an emphasis on 28- or 30-day mortality as the main measure and in-hospital or ICU mortality as the nearest surrogate of this measure. Three of the most common adverse events, namely, gastroduodenal bleeding, superinfection, and hyperglycemia, were also considered. Data Synthesis: A total of 19 studies involving 95,841 patients were included. Hydrocortisone plus fludrocortisone showed the lowest short-term mortality versus placebo (odds ratio [OR]: 0.79; 95% credible interval [CrI], 0.64–0.99; number needed to treat [NNT]: 21, range: 12–500; low certainty of evidence) in terms of informative priors. The surface under the cumulative ranking curve values for hydrocortisone plus fludrocortisone, hydrocortisone alone, and placebo were 0.9469, 0.4542, and 0.0989, respectively. Consistent results were observed in RCTs alone and those using a daily 200-mg dose of hydrocortisone. Although gastroduodenal bleeding or superinfection showed no clear increase, hyperglycemia risk increased. The ORs were 0.53 for placebo versus hydrocortisone plus fludrocortisone and 0.64 for placebo versus hydrocortisone alone, with very low certainty of evidence. Conclusions: In adults with septic shock, hydrocortisone plus fludrocortisone improved short-term survival with minimal adverse events compared with hydrocortisone alone or placebo. However, these findings are not definitive due to the limited certainty of evidence and wide NNT range. Additional large-scale, placebo-controlled RCTs are needed to provide conclusive evidence.

show abstract

mentioning

confidence: 99%

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation*

Lai,

Lai

et al. 2023

Critical Care Medicine

View full text Add to dashboard Cite

show abstract

Focus on sepsis and general intensive care medicine

Dietrich,

Bernhard,

Beynon

et al. 2023

Anaesthesiologie

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Should We Add Fludrocortisone to Hydrocortisone for Treatment of Septic Shock?

Cited by 2 publications

References 11 publications

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation*

Do We Need to Administer Fludrocortisone in Addition to Hydrocortisone in Adult Patients With Septic Shock? An Updated Systematic Review With Bayesian Network Meta-Analysis of Randomized Controlled Trials and an Observational Study With Target Trial Emulation*

Focus on sepsis and general intensive care medicine

Contact Info

Product

Resources

About